Proposed Data Collections Submitted for Public Comment and Recommendations, 36550-36551 [2013-14435]
Download as PDF
<![CDATA[
36550
Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices
Parts Closed to the Public
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
1. Procurement
2. Security
CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of
External Affairs, (202) 942–1640.
[60Day–13–13XA]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
Dated: June 13, 2013.
James B. Petri,
Secretary, Federal Retirement Thrift
Investment Board.
[FR Doc. 2013–14524 Filed 6–14–13; 11:15 am]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
HHS gives notice of a
determination concerning a petition to
add a class of employees from the
Brookhaven National Laboratory in
Upton, New York, to the Special
Exposure Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000
(EEOICPA). On June 7, 2013, the
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
SUMMARY:
All employees of the Department of
Energy, its predecessor agencies, and its
contractors and subcontractors who worked
at Brookhaven National Laboratory in Upton,
New York, from January 1, 1994, to December
31, 2007.
mstockstill on DSK4VPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 4676
Columbia Parkway, MS C–46,
Cincinnati, OH 45226, Telephone 1–
877–222–7570. Information requests can
also be submitted by email to
DCAS@CDC.GOV.
Dated: June 11, 2013.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2013–14389 Filed 6–17–13; 8:45 am]
BILLING CODE 4163–19–P
VerDate Mar<15>2010
16:52 Jun 17, 2013
Jkt 229001
Centers for Disease Control and
Prevention
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 or send
comments to Ron Otten, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an email to omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Improving HIV Prevention and
Treatment Outcomes Among HIVInfected Persons by Integrating
Community Pharmacists and Clinical
Sites into a Model of Patient-Centered
HIV Care—New—National Center for
HIV/AIDS, Viral Hepatitis, STD and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Medication Therapy Management
(MTM) is a group of pharmacist
provided services that is independent
of, but can occur in conjunction with,
provision of medication. Medication
Therapy Management encompasses a
broad range of professional activities
and cognitive services within the
licensed pharmacists’ scope of practice
and can include monitoring prescription
filling patterns and timing of refills,
checking for medication interactions,
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
patient education, and monitoring of
patient response to drug therapy.
HIV specific MTM programs have
demonstrated success in improving HIV
medication therapy adherence and
persistence. While MTM programs have
be shown to be effective in increasing
medication adherence for HIV-infected
persons, no MTM programs have been
expanded to incorporate primary
medical providers in an effort to
establish patient-centered HIV care. To
address this problem CDC has entered
into a public-private partnership with
Walgreen Company (a.k.a Walgreens
pharmacies, a national retail pharmacy
chain) to develop and implement a
model of HIV care that integrates
community pharmacists with primary
medical providers for patient-centered
HIV care. The model program will be
implemented in ten sites and will
provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model
will include the core elements of MTM
as well as additional services such as
individualized medication adherence
counseling, active monitoring of
prescription refills and active
collaboration between pharmacists and
medical clinic providers to identify and
resolve medication related treatment
problems such as treatment
effectiveness, adverse events and poor
adherence. The expected outcomes of
the model program are increased
retention in HIV care, adherence to HIV
medication therapy and viral load
suppression.
CDC requests OMB approval to collect
standardized information, from ten
project sites over the three year project
period. CDC also requests approval to
conduct one cycle of retrospective data
collection during the first year of the
three year project period. The
retrospective data collection will
provide information about clients’
baseline characteristics prior to
participation in the model program
which is needed to compare outcomes
before and after program
implementation.
Pharmacy, laboratory and medical
data will be collected through
abstraction of all participant clients’
pharmacy and medical records.
Pharmacy, laboratory and medical data
are needed to monitor retention in care,
adherence to therapy, viral load
suppression and other health outcomes.
Program specific data, such as the
number of MTM elements completed
per project site will be collected by
program. Qualitative data will be
gathered from program staff through inperson or telephone interviews.
E:\FR\FM\18JNN1.SGM
18JNN1
36551
Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices
The data collection will allow CDC to
conduct continuous program
performance monitoring which includes
identification of barriers to program
implementation, solutions to those
barriers, and documentation of client
health outcomes. Performance
monitoring will allow the model
program to be adjusted, as needed, in
order to develop a final implementation
model that is self-sustaining and which
can be used to establish similar
collaborations in a variety of clinical
settings. There is no cost to participants
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total burden
(in hours)
Type of respondent
Form name
Clinic Data Manager .........................
Pharmacist ........................................
10
10
1
1
30/60
30/60
5
5
Clinic Data Manager .........................
Clinic Data Manager .........................
Pharmacist ........................................
Clinic and pharmacy staff .................
Project clinic characteristics form .....
Project pharmacy characteristics
form.
Initial medical abstraction form ........
Follow-up medical abstraction form
Pharmacy abstraction form ..............
Interview form ...................................
10
10
10
60
1
4
4
4
50
25
25
45/60
500
1,000
1,000
180
Total ...........................................
...........................................................
........................
........................
........................
2,690
Ron A. Otten,
Director, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2013–14435 Filed 6–17–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Form CB–496. ‘‘Title IV–E
Programs Quarterly Financial Report’’.
OMB No.: 0970–0205.
Description: This report is required to
be submitted at the end of each fiscal
quarter by each State or Tribe with an
approved plan under title IV–E of the
Social Security Act to administer the
Foster Care, Adoption Assistance and
Guardianship Assistance programs. In
submitting this form, each State or
Tribal grantee meets its statutory and
regulatory requirement to report actual
program expenditures made in the
preceding fiscal quarter and to provide
an estimate of program expenditures
anticipated in the upcoming fiscal
quarter. This reporting form also
provides for the quarterly reporting of
the average number of children assisted
through each of the three programs.
The Administration for Children and
Families provides Federal funding at the
rate of 50 percent for all allowable
administrative expenditures, with
funding at higher rates for some training
costs and maintenance assistance
payments. The information collected on
this report is used to calculate quarterly
Federal grant awards issued to States
and Tribes and to assist in the oversight
of the financial management of these
programs.
With the enactment of Public Law
110–351, the ‘‘Fostering Connections to
Success and Increasing Adoptions Act
of 2008’’ (October 7, 2008), the
Guardianship Assistance program
started operation in FY 2009 and Tribes,
tribal organizations and consortia
became eligible to submit individual
title IV–E plans in FY 2010. At the time
of this request for OMB review, 33
States have had their State plan
amendments submitted and approved to
include the Guardianship program;
additional States are anticipated in the
future. To date, although only a single
Tribal title IV–E plan has been
approved, several additional Tribal
plans are in the final stages of the
review process, with approval
anticipated shortly.
Under Public Law 112–34, the ‘‘Child
and Family Services Improvement and
Innovation Act’’ (September 30, 2011),
Section 1130 of the Social Security Act
was amended to allow ACF to approve
up to ten child welfare waiver
demonstration projects in each of FYs
2012–2014. These projects are to
continue no longer than five years and
be completed no later than September
30, 2019, the end of FY 2019.
The anticipated inclusion of thirty
additional State demonstration projects
requires several additional data entry
requirements for the reporting of
demonstration project expenditures on
Part 3 of Form CB–496.
The final draft version of this form
was the result of comments in response
to several teleconference calls with
Federal and grantee staffs and a
‘webinar’’ presentation that provided
detailed discussions concerning the
reporting of demonstration project
expenditures on Part 3. Comments were
also received in response to the first
Federal Register Notice (77 FR 70165 et.
seq., November 23, 2012).
Respondents: State (including the
District of Columbia and Puerto Rico)
and Tribal title IV–E agencies
administering the Foster Care, Adoption
Assistance and Guardianship Assistance
Programs.
mstockstill on DSK4VPTVN1PROD with NOTICES
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
Form CB–496, ‘‘Title IV–E Programs Quarterly Financial Report’’ (with Part
3: ‘‘Demonstration Projects’’) .......................................................................
Form CB–496, ‘‘Title IV–E Programs Quarterly Financial Report’’ (without
Part 3: ‘‘Demonstration Projects’’) ................................................................
VerDate Mar<15>2010
16:52 Jun 17, 2013
Jkt 229001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden hours
per response
Total
burden hours
30
4
23
2,760
32
4
17
2,176
E:\FR\FM\18JNN1.SGM
18JNN1
]]>Agencies
[Federal Register Volume 78, Number 117 (Tuesday, June 18, 2013)]
[Notices]
[Pages 36550-36551]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14435]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-13-13XA]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570 or
send comments to Ron Otten, 1600 Clifton Road, MS-D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Improving HIV Prevention and Treatment Outcomes Among HIV-Infected
Persons by Integrating Community Pharmacists and Clinical Sites into a
Model of Patient-Centered HIV Care--New--National Center for HIV/AIDS,
Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Medication Therapy Management (MTM) is a group of pharmacist
provided services that is independent of, but can occur in conjunction
with, provision of medication. Medication Therapy Management
encompasses a broad range of professional activities and cognitive
services within the licensed pharmacists' scope of practice and can
include monitoring prescription filling patterns and timing of refills,
checking for medication interactions, patient education, and monitoring
of patient response to drug therapy.
HIV specific MTM programs have demonstrated success in improving
HIV medication therapy adherence and persistence. While MTM programs
have be shown to be effective in increasing medication adherence for
HIV-infected persons, no MTM programs have been expanded to incorporate
primary medical providers in an effort to establish patient-centered
HIV care. To address this problem CDC has entered into a public-private
partnership with Walgreen Company (a.k.a Walgreens pharmacies, a
national retail pharmacy chain) to develop and implement a model of HIV
care that integrates community pharmacists with primary medical
providers for patient-centered HIV care. The model program will be
implemented in ten sites and will provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model will include the core elements
of MTM as well as additional services such as individualized medication
adherence counseling, active monitoring of prescription refills and
active collaboration between pharmacists and medical clinic providers
to identify and resolve medication related treatment problems such as
treatment effectiveness, adverse events and poor adherence. The
expected outcomes of the model program are increased retention in HIV
care, adherence to HIV medication therapy and viral load suppression.
CDC requests OMB approval to collect standardized information, from
ten project sites over the three year project period. CDC also requests
approval to conduct one cycle of retrospective data collection during
the first year of the three year project period. The retrospective data
collection will provide information about clients' baseline
characteristics prior to participation in the model program which is
needed to compare outcomes before and after program implementation.
Pharmacy, laboratory and medical data will be collected through
abstraction of all participant clients' pharmacy and medical records.
Pharmacy, laboratory and medical data are needed to monitor retention
in care, adherence to therapy, viral load suppression and other health
outcomes. Program specific data, such as the number of MTM elements
completed per project site will be collected by program. Qualitative
data will be gathered from program staff through in-person or telephone
interviews.
[[Page 36551]]
The data collection will allow CDC to conduct continuous program
performance monitoring which includes identification of barriers to
program implementation, solutions to those barriers, and documentation
of client health outcomes. Performance monitoring will allow the model
program to be adjusted, as needed, in order to develop a final
implementation model that is self-sustaining and which can be used to
establish similar collaborations in a variety of clinical settings.
There is no cost to participants other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Clinic Data Manager.......... Project clinic 10 1 30/60 5
characteristics
form.
Pharmacist................... Project pharmacy 10 1 30/60 5
characteristics
form.
Clinic Data Manager.......... Initial medical 10 1 50 500
abstraction form.
Clinic Data Manager.......... Follow-up medical 10 4 25 1,000
abstraction form.
Pharmacist................... Pharmacy 10 4 25 1,000
abstraction form.
Clinic and pharmacy staff.... Interview form... 60 4 45/60 180
---------------------------------------------------------------
Total.................... ................. .............. .............. .............. 2,690
----------------------------------------------------------------------------------------------------------------
Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013-14435 Filed 6-17-13; 8:45 am]
BILLING CODE 4163-18-P
